Related Experiment Video

Updated: Aug 9, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

Prostate cancer and novel pharmacological treatment options-what's new for 2022?

Andrea Marchetti1,2, Elisa Tassinari1,2, Matteo Rosellini1,2

  • 1Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Expert Review of Clinical Pharmacology
|February 16, 2023
PubMed
Abstract

Insights

New prostate cancer (PC) therapies include triplet regimens and targeted agents. Radionuclide therapy shows promise for metastatic castration-resistant PC, but further research is needed to optimize sequencing and patient selection.

Area of Science:

  • Oncology
  • Medical Science

Background:

  • Androgen deprivation therapy (ADT) combined with androgen receptor-targeted agents (ARTAs) or docetaxel represents the current standard of care for prostate cancer (PC).
  • Established treatment options for pretreated patients include cabazitaxel, olaparib, rucaparib (for BRCA mutations), Radium-223 (for bone metastases), sipuleucel T, and 177 LuPSMA-617.

Approach:

  • This review synthesizes recent clinical trial data and explores emerging therapeutic strategies for advanced prostate cancer management.
  • Focuses on novel treatment combinations and their potential impact on patient outcomes.

Key Points:

  • Triplet therapies (ADT, chemotherapy, ARTAs) show promise, particularly in metastatic hormone-sensitive PC.
  • ARTAs combined with PARP inhibitors offer insights for metastatic castration-resistant PC, irrespective of homologous recombination status.
  • 177Lu-PSMA-617 demonstrates efficacy in pretreated metastatic castration-resistant PC.

Conclusions:

  • Ongoing research into combination therapies like immunotherapy plus PARPi or chemotherapy yields varied results, necessitating further investigation.
  • Future research will clarify optimal patient selection and treatment sequencing for various advanced PC strategies.
Keywords:
ARSIARTAPARP-inhibitorProstate cancercabazitaxeldocetaxeltheranostic

More Related Videos

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.4K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
238
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
469
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
213